PIK3CA is activated through mutation in ~ 35% of cases, most of which do not show amplification of ErbB2. Thus, collectively, ERBB2/Neu+ and PIK3CAmutant breast tumors represent the majority of cases. This evidence concerns the gene ERBB2 and breast neoplasm.